564 related articles for article (PubMed ID: 17652818)
21. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
Platel D; Bonoron-Adèle S; Dix RK; Robert J
Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608
[TBL] [Abstract][Full Text] [Related]
22. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
23. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
24. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
25. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
26. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman EH; Ferrans VJ
Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
28. Anthracycline-induced cardiomyopathy.
Keefe DL
Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
30. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
31. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
32. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
[TBL] [Abstract][Full Text] [Related]
33. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
34. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the prevention of anthracycline cardiotoxicity in childhood.
Iarussi D; Indolfi P; Casale F; Coppolino P; Tedesco MA; Di Tullio MT
Curr Med Chem; 2001 Nov; 8(13):1649-60. PubMed ID: 11562284
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
37. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
38. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
39. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
40. [Cardiotoxicity of anthracyclines].
Laurent S; Colbert N; Izrael V; Motte G
Ann Med Interne (Paris); 1984; 135(6):464-72. PubMed ID: 6391323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]